-
ChatGPT: A new horizon at the intersect of human and artificial intelligence in academic psychiatry Bipolar Disord. (IF 5.4) Pub Date : 2024-04-20 Russell Franco D’Souza, Shabbir Amanullah, Mary Mathew, Rajiv Tandon, Krishna Mohan Surapaneni
-
Early warning signals observed in motor activity preceding mood state change in bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2024-04-19 Petter Jakobsen, Ulysse Côté‐Allard, Michael Alexander Riegler, Lena Antonsen Stabell, Andrea Stautland, Tine Nordgreen, Jim Torresen, Ole Bernt Fasmer, Ketil Joachim Oedegaard
IntroductionAlterations in motor activity are well‐established symptoms of bipolar disorder, and time series of motor activity can be considered complex dynamical systems. In such systems, early warning signals (EWS) occur in a critical transition period preceding a sudden shift (tipping point) in the system. EWS are statistical observations occurring due to a system's declining ability to maintain
-
Psychological therapies for people with bipolar disorder: Where are we now, and what is next? ISBD Psychological Interventions Taskforce—Position paper Bipolar Disord. (IF 5.4) Pub Date : 2024-04-18 Kim Wright, Manja Koenders, Katie M. Douglas, Maria Faurholt‐Jepsen, Kathryn E. Lewandowski, David J. Miklowitz, Emma Morton, Greg Murray, Thomas Richardson, Luisa de Siqueira Rotenberg, Sarah H. Sperry, Anna R. Van Meter, Andrea B. Vassilev, Luisa Weiner, Lauren M. Weinstock, Esther Mesman
-
Supporting career development for early‐ and mid‐career professionals working in the bipolar disorder field: Key initiatives to be implemented by the International Society for Bipolar Disorders Early‐ and Mid‐Career Committee Bipolar Disord. (IF 5.4) Pub Date : 2024-04-16 Katie M. Douglas, Sarah H. Sperry, Olivia M. Dean, Gabriel R. Fries, Fabiano A. Gomes, Joanna Jiménez Pavón, Emma Morton, Rachel H. B. Mitchell, Tamsyn E. Van Rheenen, Norma Verdolini, Ni Xu, Georgina M. Hosang, Rebekah S. Huber
CONFLICT OF INTEREST STATEMENT KMD uses software provided free of charge by Scientific Brain Training Pro for Cognitive Remediation trials. KMD would like to acknowledge salary support from the Health Research Council of New Zealand (Sir Charles Hercus Health Research Fellowship; ref: 19/082). OMD has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical
-
Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder Bipolar Disord. (IF 5.4) Pub Date : 2024-04-13 Roger S. McIntyre, Bethany Davis, Jane Rodgers, Ludmyla Rekeda, Julie Adams, Lakshmi N. Yatham
IntroductionCariprazine treats acute manic and depressive episodes in bipolar I disorder (BP‐I), but its efficacy in preventing relapse of mood episode remains unknown.MethodsIn this phase 3b, double‐blind, placebo‐controlled study, patients with BP‐I with acute manic or depressive episodes (each with/without mixed features), were treated with cariprazine 3.0 mg/day during a 16‐week open‐label treatment
-
Anti‐manic effect of deep brain stimulation of the ventral tegmental area in an animal model of mania induced by methamphetamine Bipolar Disord. (IF 5.4) Pub Date : 2024-04-01 Roger B. Varela, Suelen L. Boschen, Nathanael Yates, Tristan Houghton, Charles D. Blaha, Kendall H. Lee, Kevin E. Bennet, Abbas Z. Kouzani, Michael Berk, João Quevedo, Samira S. Valvassori, Susannah J. Tye
BackgroundTreatment of refractory bipolar disorder (BD) is extremely challenging. Deep brain stimulation (DBS) holds promise as an effective treatment intervention. However, we still understand very little about the mechanisms of DBS and its application on BD.AimThe present study aimed to investigate the behavioural and neurochemical effects of ventral tegmental area (VTA) DBS in an animal model of
-
A tale of two viruses: A bipolar disorder patient's path to Varicella Zoster Meningoencephalitis diagnosis in the pandemic era Bipolar Disord. (IF 5.4) Pub Date : 2024-03-27 Johannes Piepgras, Max Scheller, Susanne Englisch
Key Message The labyrinth of psychiatric diagnoses can often be puzzling, and sometimes, the true pathogenesis lurks within the complex interplay between psychiatric and organic disorders. A high index of suspicion, combined with a broadened diagnostic perspective, is crucial in such scenarios. This case offers an important reminder of the intricate ways in which viral pathogens can affect the CNS
-
Machine-based learning of multidimensional data in bipolar disorder – pilot results Bipolar Disord. (IF 5.4) Pub Date : 2024-03-26 Armin Birner, Marco Mairinger, Clemens Elst, Alexander Maget, Frederike T. Fellendorf, Martina Platzer, Robert Queissner, Melanie Lenger, Adelina Tmava-Berisha, Susanne A. Bengesser, Eva Z. Reininghaus, Markus Kreuzthaler, Nina Dalkner
Owing to the heterogenic picture of bipolar disorder, it takes approximately 8.8 years to reach a correct diagnosis. Early recognition and early intervention might not only increase quality of life, but also increase life expectancy as a whole in individuals with bipolar disorder. Therefore, we hypothesize that implementing machine learning techniques can be used to support the diagnostic process of
-
A case of pregnancy with severe polyhydramnios related to long‐term use of lithium Bipolar Disord. (IF 5.4) Pub Date : 2024-03-26 Aldo Stoppa, Ester Roda, Lluïsa Garcia‐Esteve, Alba Roca‐Lecumberri
ObjectivesSevere polyhydramnios during pregnancy may be associated with long‐term lithium use and presents considerable challenges. This complication, which has been linked to induced nephrogenic diabetes insipidus (NDI), underscores the necessity for cautious management of pregnant women with bipolar disorder. This case report aims to elucidate the relationship between long‐term lithium use, pregnancy
-
Vitamin B12 overdose may trigger the onset of mixed‐state bipolar disorder: A case report Bipolar Disord. (IF 5.4) Pub Date : 2024-03-22 Albert Stachura, Łukasz Banaszek, Katarzyna Jurkin, Łukasz Święcicki
CONFLICT OF INTEREST STATEMENT All authors declare that they have no conflicts of interest.
-
Cannabis withdrawal and manic episodes: Three cases of an unknown trigger for bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2024-03-21 Sergi Salmerón, Iñaki Ochandiano, Helena Andreu, Luis Olivier, Oscar de Juan, Tabatha Fernández‐Plaza, Lorenzo Bracco, Lluc Colomer, Pablo Barrio, Marc Valentí, Anna Giménez‐Palomo, Eduard Vieta, Isabella Pacchiarotti
CONFLICT OF INTEREST STATEMENT EV has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis and Takeda. IP has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck
-
The critical role of mentorship in academic career development: A commentary on proposed initiatives by the International Society for Bipolar Disorders Early Mid-Career Committee Bipolar Disord. (IF 5.4) Pub Date : 2024-03-18 Gabriel R. Fries, Sarah H. Sperry, Tamsyn E. Van Rheenen, Emma Morton
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Challenges and missed opportunities in lithium monitoring for bipolar disorder: A reflection on Bosi et al.'s finding Bipolar Disord. (IF 5.4) Pub Date : 2024-03-18 Thalles Rodrigues Alves Leite, Sergio Andre de Souza Junior, Ana Leticia Souza da Silva, Sarah Pereira Gomes, Fabio Gomes de Matos e Souza, Luisa Weber Bisol
CONFLICT OF INTEREST STATEMENT There are no conflicts of interest or disclosures to declare.
-
Is maintenance therapy warranted for recurrent mania in a woman with a positive family history of Huntington's disease? Bipolar Disord. (IF 5.4) Pub Date : 2024-03-14 Amarins Gaastra, Erik van Duijn, Annemiek Dols
1 CASE PRESENTATION A 63-year-old woman visited our outpatient clinic 2 months after being involuntarily admitted for a manic psychotic episode. She had been convinced that a bomb would hit her home and that she could talk to angels. When she was admitted, she was initially reluctant to take medication, but she quickly recovered with 10 mg of olanzapine per day and she was discharged after 3 weeks
-
-
Antidepressant monotherapy in treatment‐refractory bipolar II depression Bipolar Disord. (IF 5.4) Pub Date : 2024-03-14 Takeshi Terao
CONFLICT OF INTEREST STATEMENT Interests from the past 3 years are as follows. Dr. Terao received speaker's honoraria from Sumitomo Pharma, Shionogi, Otsuka, Eisai, Daiichi Sankyo, Janssen, Viatris, Takeda, Meiji, Mochida, MSD, and Tanabe-Mitsubishi (Yoshitomi).
-
Advancing clinical practice and discovery research through revised taxonomy: Case in point bipolar disorder diagnosis Bipolar Disord. (IF 5.4) Pub Date : 2024-03-08 Anne Duffy, Paul Grof
In the well-articulated paper by Malhi et al.1 in this journal, several problems with diagnosing bipolar disorder in children are discussed and as rightly pointed out “impede our ability to conduct meaningful research and advance clinical practice”. In fact, one could argue that the diagnostic challenges outlined apply to the diagnoses of mood disorders more generally. That is, reliance on a diagnostic
-
Efficacy and safety of established and off‐label ADHD drug therapies for cognitive impairment or attention‐deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force Bipolar Disord. (IF 5.4) Pub Date : 2024-03-04 Kamilla W. Miskowiak, Zacharias K. Obel, Riccardo Gugliemo, Caterina del Mar Bonnin, Christopher R. Bowie, Vicente Balanzá‐Martínez, Katherine E. Burdick, Andre F. Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Lars V. Kessing, Beny Lafer, Kathryn E. Lewandowski, Carlos López‐Jaramillo, Anabel Martinez‐Aran, Roger S. McIntyre, Richard J. Porter, Scot E. Purdon, Ayal Schaffer, Paul R. A.
BackgroundAbnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention‐deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off‐label ADHD therapies in BD.MethodsWe
-
Experts by lived experience: Enhancing the patient-provider relationship through patient stories Bipolar Disord. (IF 5.4) Pub Date : 2024-02-21 Tammy Hua, Gregg Martin, Alex Leow
CONFLICT OF INTEREST STATEMENT AL is a cofounder of KeyWise AI and has served as a medical and/or scientific advisor for Otsuka, USA and Buoy Health. All other authors have no conflicts of interest to declare.
-
Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review Bipolar Disord. (IF 5.4) Pub Date : 2024-02-07 Rakesh Kumar, Nicolas A. Nuñez, Neha Joshi, Boney Joseph, Alessandra Verde, Ashok Seshadri, Alfredo B. Cuellar Barboza, Larry J. Prokop, Gustavo C. Medeiros, Balwinder Singh
Ketamine is increasingly used for treatment-resistant depression (TRD) while its mechanism of action is still being investigated. In this systematic review, we appraise the current evidence of metabolomic biomarkers for racemic ketamine and esketamine in patients with TRD and healthy controls (HCs).
-
Late-onset delirious mania: Does it ring a bell? Bipolar Disord. (IF 5.4) Pub Date : 2024-02-06 Maria Aa Hansen, Robert Bering, Anders Spanggård, Pedro Barata
Bell's mania was first described in 1849, and other terms have been used to describe this condition, including delirious mania, mania with delirium, and excited delirium. However, no international diagnostic manual has included mania as an independent diagnostic tool. The criteria for delirious mania were proposed by Bond et al.
-
Anhedonia in bipolar depression treated with ketamine Bipolar Disord. (IF 5.4) Pub Date : 2024-02-04 Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska-Leszczuk, Maria Gałuszko-Węgielnik, Wiesław J. Cubała
Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently, there is no approved
-
Is peripartum anhedonia a missing target? Bipolar Disord. (IF 5.4) Pub Date : 2024-02-01 Marianna Mazza, Giuseppe Marano
The perinatal period is an extremely delicate phase that can involve a high risk for onset of depressive disorders. The Edinburgh Postnatal Depression Scale (EPDS) is a widely validated instrument for assessing perinatal depressive symptoms, including the dimension of anhedonia. There are studies suggesting that the neural mechanism underlying the occurrence of anhedonia in patients with major depressive
-
Correction to “Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2)” Bipolar Disord. (IF 5.4) Pub Date : 2024-01-29
C. M. Altimus, E. G. Baxi, M. A. Frye, E. J. Nestler, D. L. Pham, K. E. Burdick (2023) Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2). Bipolar Disorders, 25, 619–623. The below Funding Statement was not included when the above article originally published and has been now added to the article. Funding related to this publication was
-
Fostering networking opportunities and creating a community of early and mid-career clinicians and researchers within the International Society for Bipolar Disorders Bipolar Disord. (IF 5.4) Pub Date : 2024-02-01 Fabiano A. Gomes, Rebekah S. Huber, Sarah H. Sperry, Tamsyn E. Van Rheenen
The International Society for Bipolar Disorders (ISBD) recognizes that empowering the next generation of professionals focused on bipolar disorder is critical for both the scientific progress of the discipline but also its survival as an organization. The Early and Mid-Career Committee (EMCC) was established to provide a platform from which the ISBD could nurture and support the career development
-
Occurrence of postpartum manic or mixed episodes in women with bipolar I disorder: A systematic review and meta-analysis Bipolar Disord. (IF 5.4) Pub Date : 2024-01-23 Verinder Sharma, Katelyn N. Wood, Bruce Weaver, Dwight Mazmanian, Michael Thomson
Accurate information on the frequency and prevalence of manic or mixed episodes is important for therapeutic, prognostic, and safety concerns. We aimed to estimate the risk of relapse of manic and mixed episodes after delivery in women with bipolar I disorder or schizoaffective disorder—bipolar type.
-
Valproate-induced hyperammonemia, neuroleptic sensitivity, and cerebellar atrophy—A clinical conundrum in the management of bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2024-01-22 Samarth S. Shetty, Harshitha H. AnnajiGowda, Ajit Bhalchandra Dahale
Treatment of bipolar disorder (BD) involves complexities especially when patients come with significant sensitivity to various psychotropic medications and comorbidities. The following cases aim to recapitulate and discuss some of such situations.
-
Myelinolysis cases presenting with manic attack after rapid correction of hyponatremia: Two cases Bipolar Disord. (IF 5.4) Pub Date : 2024-01-18 Muhammed Emin Boylu, İsmet Kırpınar
Myelinolysis is a neurological condition that can display diverse psychiatric symptoms, with electrolyte imbalance, alcoholism and malnutrition being the frequent causes. Rapid correction of hyponatremia may trigger pontine and extra-pontine myelinolysis.
-
Comment on published article “A chat about bipolar disorder” Bipolar Disord. (IF 5.4) Pub Date : 2024-01-18 Hinpetch Daungsupawong, Viroj Wiwanitkit
To the Editor, we follow the topic “A chat about bipolar disorder1”. According to the study's findings, ChatGPT proved its ability to deliver basic and informative information on bipolar disorders.
-
Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2) Bipolar Disord. (IF 5.4) Pub Date : 2023-12-21 C. M. Altimus, E. G. Baxi, M. A. Frye, E. J. Nestler, D. L. Pham, K. E. Burdick
CONFLICT OF INTEREST STATEMENT CMA, EGB, EJN, and DLP have nothing to disclose. MAF receives grant support from Assurex Health; honoraria from Carnot Laboratories and American Physician Institute; and has a financial interest in Chymia LLC. KEB receives honoraria from Merck.
-
Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder Bipolar Disord. (IF 5.4) Pub Date : 2023-12-14 Jin-jie Xu, Chunfeng Xiao, Yanli Pan, Yi-lang Tang, Mingwan Wang, Sheng Li, Gaoming Xie, Jing Du, Yanping Ren, Wei Wang
We report the case of a Chinese male with schizoaffective disorder, an active smoker and a nonresponder to clozapine (600 mg daily). Therapeutic clozapine monitoring was analyzed, revealing a low concentration-dose ratio. A pharmacogenetic test showed that the patient had the CYP1A2*1F/*1F genotype, indicating an ultra-rapid clozapine metabolizer. In combination with fluvoxamine, a CYP1A2 enzyme inhibitor
-
Breaking tradition: A case report on successfully treating psoriasis in a patient with bipolar disorders using biologics, without discontinuing lithium Bipolar Disord. (IF 5.4) Pub Date : 2023-12-06 Francesco Cuniberti, Simone Ribero, Michela Ortoncelli, Cecilia Avetta, Paolo Leombruni, Francesco Oliva
CONFLICT OF INTEREST STATEMENT The authors have no conflict of interest to declare.
-
Aversive agents: Think twice. A case report on disulfiram-induced mania Bipolar Disord. (IF 5.4) Pub Date : 2023-11-27 María Fernanda González-Romero, José María Martínez-Ávila, Elizabeth Moloney, Ignacio García-Cabeza
We present a case of disulfiram-induced mania in a patient with both alcohol use disorder (AUD) and psychostimulant use disorder (PUD), without a history of psychosis or mania. This acute presentation may be linked to the increased dopamine levels caused by disulfiram metabolism. Our patient developed manic symptoms 10 days after starting disulfiram, prescribed to treat the AUD. It should be noted
-
History of the International Society for Bipolar Disorders: 30 years and counting Bipolar Disord. (IF 5.4) Pub Date : 2023-11-23 Holly A. Swartz, Chad Daversa, Ellen Frank
CONFLICT OF INTEREST STATEMENT Dr. Swartz has served as a consultant for Intracellular Therapies, Medscape/WebMD, Physicians Postgraduate Press, Clinical Education Alliance, and Mediflix. She receives royalties from American Psychiatric Association Publishing and Wolters Kluwer (UpToDate). Dr. Frank is an employee of Health Rhythms, Inc. and holds equity in Health Rhythms, Inc. and Adaptive Testing
-
Maternal early pregnancy body mass index and bipolar disorder in the offspring Bipolar Disord. (IF 5.4) Pub Date : 2023-11-20 Rachael J. Beer, Sven Cnattingius, Ezra S. Susser, Lu Wang, Eduardo Villamor
To investigate the association between maternal early pregnancy body mass index (BMI) and offspring bipolar disorder (BPD).
-
From knowledge gaps to career opportunities: The early- to Mid-Career Committee's impact on increasing resources for bipolar disorder professionals Bipolar Disord. (IF 5.4) Pub Date : 2023-11-20 Joanna Jiménez-Pavón, Olivia M. Dean, Georgina M. Hosang, Katie M. Douglas, Rebekah S. Huber, Rachel H. B. Mitchell
CONFLICT OF INTEREST STATEMENT JJP acknowledges financial support from the CONAHCYT's National System of Researchers (SNI) of Mexico. RHBM acknowledges salary support from Academic Scholar Awards from the Department of Psychiatry at the University of Toronto and Sunnybrook Health Sciences Centre and an honourarium from Medscape. OMD has received grant support from the Brain and Behavior Foundation
-
Shifting from prevention of the next episode to optimizing inter-episodic functioning Commentary on “The neuroprogression hypothesis in bipolar disorders: Time for apologies?” Bipolar Disord. (IF 5.4) Pub Date : 2023-11-20 Annemiek Dols, Sigfried Schouws, Melis Orhan, Alexandra Beunders
The question in science is: at what point is there enough evidence to shift paradigm? Strejilevich and colleagues argue in their editorial that the time is here for bipolar disorder (BD).1 The authors argue that we have not been able to prove neuroprogression in BD and that holding on to it will harm patients. A (hyper)focus on prevention of new episodes in BD may lead to overprescribing medication
-
Unmasking bipolarity in recurrent depressive disorder following herpes simplex virus triggered n-methyl-D-aspartate encephalitis Bipolar Disord. (IF 5.4) Pub Date : 2023-11-16 Karthik Narasimhappa, Harkishan Mamtani, Kshiteeja Jain, Vikram V. Holla, Sundarnag Ganjekar, Netravathi Manjunath, Karthik Kulanthaivelu, Geetha Desai
Herpes simplex virus (HSV) infection triggered n-methyl-D-aspartate (NMDA) encephalitis can lead to varied neuropsychiatric manifestations, including movement disorders and manic symptoms. HSV is known to affect the same brain regions as in secondary mania.
-
Processing speed and sustained attention in bipolar disorder and major depressive disorder: A systematic review and meta-analysis Bipolar Disord. (IF 5.4) Pub Date : 2023-11-16 Bethany Little, Megan Anwyll, Laura Norsworthy, Luke Corbett, Mia Schultz-Froggatt, Peter Gallagher
Cognitive impairment is a core feature of bipolar disorder (BD) and major depressive disorder (MDD). Deficits in processing speed (PS) and sustained attention (SA) may be particularly impaired and may underpin a broader profile of deficits, however current knowledge of the nature of these impairments is limited by heterogeneous results in the literature. Few reviews to date have attempted to disentangle
-
Concurrent lithium and haemodialysis treatment: Clinical recommendations based on the literature and a multicentre survey Bipolar Disord. (IF 5.4) Pub Date : 2023-11-15 Wytse J. Kuiper, Koen P. Grootens, Angèle P. M. Kerckhoffs
Lithium has an irreplaceable role in the treatment of severe mood disorders, but declining renal function associated with its use leads to clinical dilemmas. Although not often applied, and requiring close monitoring and multidisciplinary actions, concurrent lithium and haemodialysis treatment (CLHT) is a feasible option. To our knowledge, however, there are no detailed consensus- or evidence-based
-
Is intravenous valproate more efficacious than oral valproate for inpatients with bipolar I disorder with a manic or depressive episode and concomitant symptoms of opposite polarity? Bipolar Disord. (IF 5.4) Pub Date : 2023-11-13 Alessandro Cuomo, Giovanni Barillà, Matteo Cattolico, Pietro Carmellini, Alessandro Spiti, Andrea Pozza, Andrea Fagiolini
Valproic acid (VPA) is a commonly prescribed mood stabilizer, available in both oral (OS) and intravenous (IV) formulations. However, few studies have compared their safety and efficacy. This retrospective study aimed to investigate the safety and efficacy of and IV-VPA in patients with Bipolar Disorder.
-
Heterogeneity in the longitudinal courses of global functioning in children at familial risk of major psychiatric disorders: Association with trauma and familial characteristics Bipolar Disord. (IF 5.4) Pub Date : 2023-11-13 Alexandre Bureau, Nicolas Berthelot, Jasmin Ricard, Camille Lafrance, Valérie Jomphe, Abdoulaye Dioni, Énora Fortin-Fabbro, Marie-Claude Boisvert, Michel Maziade
The extent to which heterogeneity in childhood risk trajectories may underlie later heterogeneity in schizophrenia (SZ), bipolar disorder (BP), and major depressive disorder (MDD) remains a chief question. Answers may optimally be found by studying the longitudinal trajectories of children born to an affected parent. We aimed to differentiate trajectories of global functioning and their sensitive periods
-
Challenges in defining treatment-resistant mania in adults: A systematic review Bipolar Disord. (IF 5.4) Pub Date : 2023-11-14 Christina Gonzalez-Torres, Benoit H. Mulsant, M. Ishrat Husain, Martin Alda, Robert C. Young, Abigail Ortiz
To review the definitions of treatment-resistant mania (TRM) in the literature and propose criteria for an operationalized definition.
-
Letter to editor: Bipolar disorders Bipolar Disord. (IF 5.4) Pub Date : 2023-11-07 Robert H. Belmaker
It was surprising to read the editorial by Malhi and Bauer1 in the last issue of bipolar disorders entitled “Lithium First: Not Merely First Line.” I was unsure of the reason for the authors' triumphalist tone, since all the references were well known and nothing new. I have spent a large part of my 50-year research and clinical psychopharmacology career studying lithium biochemically and in animal
-
Use of botulinum toxin A for depression symptoms in patients with treatment-resistant bipolar illness: A case series Bipolar Disord. (IF 5.4) Pub Date : 2023-11-05 Ali A. Farooqui, Jessica M. Fulkerson, Rif S. El-Mallakh
CONFLICT OF INTEREST STATEMENT Dr. El-Mallakh has research funding from Sunovion and is on the speakers' bureau of Axsome, Intracellular, Janssen, Lundbeck, Myriad, Noven, Otsuka, and Teva. Dr. Farooqui is on the speaker's bureau of Abbvie and BioXcel.
-
Bipolar disorder assessment and monitoring measures in clinical care: Updates from a large randomized controlled trial in primary care Bipolar Disord. (IF 5.4) Pub Date : 2023-11-03 Joseph M. Cerimele, John C. Fortney
CONFLICT OF INTEREST STATEMENT The authors report no conflicts of interest.
-
Disulfiram-induced mania: A case report Bipolar Disord. (IF 5.4) Pub Date : 2023-11-02 Jessica Batten, Vijay Gorrepati, Tawny Smith, David Spelber, Jorge Almeida
CONFLICT OF INTEREST STATEMENT The authors of this article have no conflict of interest to disclose.
-
Demographic and clinical associations to employment status in older-age bipolar disorder: Analysis from the GAGE-BD database project Bipolar Disord. (IF 5.4) Pub Date : 2023-10-05 Amulya Mallu, Carol K. Chan, Lisa T. Eyler, Annemiek Dols, Soham Rej, Hilary P. Blumberg, Kaylee Sarna, Brent P. Forester, Regan E. Patrick, Orestes V. Forlenza, Esther Jimenez, Eduard Vieta, Sigfried Schouws, Ashley Sutherland, Joy Yala, Farren B. S. Briggs, Martha Sajatovic
The current literature on employment in older adults with bipolar disorder (OABD) is limited. Using the Global Aging and Geriatric Experiments in Bipolar Disorder Database (GAGE-BD), we examined the relationship of occupational status in OABD to other demographic and clinical characteristics.
-
A chat about bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2023-09-28 Gordon Parker, Michael J. Spoelma
This study aimed to assess the capabilities of ChatGPT (Chat Generative Pre-Trained Transformer) in generating informative content related to bipolar disorders. The objectives were to evaluate its ability to provide accurate information on symptoms, classification, causes, and management of bipolar disorder and to explore its creativity in generating topic-related songs.
-
Multi-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode Bipolar Disord. (IF 5.4) Pub Date : 2023-09-25 Jay D. Amsterdam, Colin Xu
Few studies have systematically examined the safety and effectiveness of antidepressant versus mood stabilizer monotherapy of bipolar II depression. To date, there are no aggregated or mega-analyses of prospective trials of individual participant-level data (IPD) to inform future treatment guidelines on the relative safety and effectiveness of antidepressant or lithium monotherapy.
-
Dark skies before the storm: The Chronos syndrome Bipolar Disord. (IF 5.4) Pub Date : 2023-09-25 Pierre A. Geoffroy
Dear Editor, Bipolar disorders recently published an intriguing study indicating that 6.1% of individuals with subthreshold manic symptoms progressed to a full-blown hypomanic or manic episode during a 3-year follow-up.1 The study also identified 11 risk factors associated with this unfavorable course, with the most significant ones being a history of depression or dysthymia, living without a partner
-
Erratum Bipolar Disord. (IF 5.4) Pub Date : 2023-09-19
In the article by Montejo et al.,1 the following sentence was missed in the Acknowledgments section: “Projects PI17/01066 and PI20/00344, funded by the Instituto de Salud Carlos III and cofunded by the European Union (FEDER) (“Una manera de hacer Europa”).” We apologize for this oversight.
-
Low and very low lithium levels: Thyroid effects are small but still require monitoring Bipolar Disord. (IF 5.4) Pub Date : 2023-09-13 James Phelps, Olivia Pipitone Coskey
Low doses of lithium, as might be used for mood or dementia prevention, do not carry the same renal, toxicity, and tolerability problems of doses used for prophylaxis or treatment of mania. However, thyroid effects of low doses have not been investigated. Our goal in this study was to assess the changes in thyroid-stimulating hormone (TSH) associated with a broad range of lithium levels, including
-
“The neuroprogression hypothesis in bipolar disorders: Time for apologies?” Bipolar Disord. (IF 5.4) Pub Date : 2023-08-14 Sergio A. Strejilevich, Cecilia Samamé, Danilo Quiroz
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.
-
Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report Bipolar Disord. (IF 5.4) Pub Date : 2023-08-10 Renato de Filippis, Pasquale De Fazio
CONFLICT OF INTEREST STATEMENT Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest.
-
Sleep patterns among preschool offspring of parents with and without psychopathology: Association with the development of psychopathology in childhood Bipolar Disord. (IF 5.4) Pub Date : 2023-08-09 Jessica C. Levenson, Heather M. Joseph, John Merranko, Danella M. Hafeman, Kelly Monk, Benjamin I. Goldstein, David Axelson, Dara Sakolsky, Rasim S. Diler, Tina Goldstein, Boris Birmaher
Disturbed sleep during early childhood predicts social–emotional problems. However, it is not known how various early childhood sleep phenotypes are associated with the development of childhood psychopathology, nor whether these relationships vary as a function of parental psychopathology. We identified sleep phenotypes among preschool youth; examined whether these phenotypes were associated with child
-
Obsessive–compulsive disorder as the onset of bipolar disorder in adolescence Bipolar Disord. (IF 5.4) Pub Date : 2023-08-09 Ester di Giacomo, Federica Moretti, Fabrizia Colmegna, Massimo Clerici
The onset of bipolar disorder (BD) usually occurs during adolescence or early adulthood. Several studies show an alarming duration of untreated illness (5 years) with 60% of people with BD reporting 1–4 different diagnoses before that of BD, with consequent treatment delay. In recent years, a growing interest in preliminary phases of BD or sub-syndromic signs has been reported. Obsessive–compulsive
-
Lithium and long-term renal effects: A complex clinical concern Bipolar Disord. (IF 5.4) Pub Date : 2023-08-08 Michael Gitlin
Potential nephrotoxicity from long-term lithium use has been well documented for many decades, with the first paper demonstrating structural renal damage, primarily in the form of interstitial nephritis (with scarring of the interstitium, tubular destruction and relative preservation of glomeruli), published in 1977.1 The trajectory of renal function in patients who have had lithium treatment discontinued
-
Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice Bipolar Disord. (IF 5.4) Pub Date : 2023-08-06 Yanling Zhou, Xiaoyu Chen, Yuping Ning
CONFLICT OF INTEREST STATEMENT I declare no competing interests.
-
The impact of body mass index on the clinical features of bipolar disorder: A STEP-BD study Bipolar Disord. (IF 5.4) Pub Date : 2023-08-03 Bashkim Kadriu, Zhi-De Deng, Christoph Kraus, Jenessa N. Johnston, Adam Fijtman, Ioline D. Henter, Siegfried Kasper, Carlos A. Zarate
The effects of body mass index (BMI) on the core symptoms of bipolar disorder (BD) and its implications for disease trajectory are largely unexplored.